Osteosarcoma medical therapy

Revision as of 17:34, 23 September 2015 by Suveenkrishna Pothuru (talk | contribs)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Osteosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Osteosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Osteosarcoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Osteosarcoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Osteosarcoma medical therapy

CDC on Osteosarcoma medical therapy

Osteosarcoma medical therapy in the news

Blogs on Osteosarcoma medical therapy

Directions to Hospitals Treating Osteosarcoma

Risk calculators and risk factors for Osteosarcoma medical therapy

Overview

Medical Therapy

Current standard treatment is to use neoadjuvant chemotherapy (chemotherapy given before surgery) followed by surgical resection. The percentage of tumor cell necrosis (cell death) seen in the tumor after surgery gives an idea of the prognosis and also lets the oncologist know if the chemotherapy regimen should be altered after surgery.

Standard therapy is a combination of limb-salvage orthopedic surgery and a combination of high dose methotrexate with leucovorin rescue, intra-arterial cisplatin caffeine, adriamycin, ifosfamide with mesna, BCD, etoposide, muramyl tri-peptite (MTP).

Ifosfamide can be used as an adjuvant treatment if the necrosis rate is low.

3-year event free survival ranges from 50% to 75% and 5-year survival ranges from 60% to 85% in some studies. Osteosarcoma has one of the lowest survival rates for pediatric cancer despite chemotherapy's success in osteosarcoma of 6 chemotherapies, interferon-alpha, interleukin-2, and being the prototype of solid tumors in cancer.

Fluids are given for hydration.

Drugs like Kytril and Zofran help with nausea and vomiting.

Neupogen, epogen, Neulasta help with white blood cell counts and neutrophil counts.

Blood helps with anemia.

Samarium

  • Samarium is a radioactive drug that targets areas where bone cells growing, such as tumor cells in bone.
  • It helps relieve pain caused by cancer in the bone and it also kills bloodcells in bone marrow.
  • Treatment with samarium may be followed by stem cell transplant.
  • Before treatment with samarium, stem cells (immature blood cells) are removed from the blood or bonemarrow of the patient and are frozen and stored. After treatment with samarium is complete, the stored stem cells are thawed and given back to the patient through an infusion. These re-infused stem cells grow into (and restore) the body's blood cells.


References

Template:WH Template:WS